Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Michele Merli, MD, Benedetta Bianchi, MD, Lorenza Bertù, Andrea Ferrario, MD, Barbara Mora, Silvia Uccella, MD, Daniela Furlan, Maria Grazia Tibiletti, Simona Cattaneo, Fausto Sessa, Prof., Francesco Passamonti, Prof.

Blood (2019) 134 (Supplement_1): 4017.

https://doi.org/10.1182/blood-2019-130288

Published: 2019

Journal Articles

Oncogenic Cooperation between EGR1 and BRD4 in Diffuse Large B Cell Lymphoma

Lixin Rui, PhD

Blood (2019) 134 (Supplement_1): 1508.

https://doi.org/10.1182/blood-2019-124839

Published: 2019

Journal Articles

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

Xin Xu

Blood (2019) 134 (Supplement_1): 5046.

https://doi.org/10.1182/blood-2019-126763

Published: 2019

Journal Articles

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Sattva S Neelapu, MD, John M. Rossi, MS, Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Patrick M Reagan, MD, Scott J Rodig, MD PhD, Lazaros J. Lekakis, MD, Ian W. Flinn, MD PhD, Lianqing Zheng, PhD, Francesca Milletti, PhD, Edmund Chang, PhD, Allen Xue, PhD, Vicki Plaks, PhD, Jenny J. Kim, MD MS, Adrian Bot, MD PhD

Blood (2019) 134 (Supplement_1): 203.

https://doi.org/10.1182/blood-2019-126218

Published: 2019

Journal Articles

Myc and the Warburg Effect

Stefano Casola, MD PhD, Gabriele Varano, Laura Perucho, Marianna Ossorio, Federica Zanardi, Martina Sormani, Valentina Petrocelli, Christin Zasada, Stefan Kempa, Klaus Rajewsky, Maurilio Ponzoni, MD, Fabio Facchetti

Blood (2018) 132 (Supplement 1): SCI-12.

https://doi.org/10.1182/blood-2018-99-109471

Published: 2018

Journal Articles

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Nathan Singh, MD, Olga Shestova, PhD, Katharina Hayer, Albert Hong, Pranali Ravikumar, MS, Atushi Hoshino, MD PhD, Ophir Shalem, PhD, Matthew D. Weitzman, PhD, Carl H June, MD, Saar I. Gill, MDPhD, Marco Ruella, MD

Blood (2018) 132 (Supplement 1): 698.

https://doi.org/10.1182/blood-2018-99-117328

Published: 2018

Journal Articles

Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling

Mahya Mehrmohamadi, PhD, Mohammad S Esfahani, PhD, Joanne Soo, BS, Florian Scherer, MD, Joseph G Schroers-Martin, MD, Binbin Chen, BS, David M. Kurtz, MDPhD, Emily Hamilton, BS, Chih Long Liu, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MDPhD

Blood (2018) 132 (Supplement 1): 672.

https://doi.org/10.1182/blood-2018-99-119361

Published: 2018

Journal Articles

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Jean Oak, MD PhD, Jay Y. Spiegel, MD, Bita Sahaf, PhD, Yasodha Natkunam, MD PhD, Steven R. Long, MD, Nasheed Hossain, MD, Crystal L. Mackall, MD, Katherine A. Kong, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2018-99-120206

Published: 2018

Journal Articles

The cells are ambiguous, not the message

Pierre S. Rohrlich

Blood (2018) 132 (3): 239–240.

https://doi.org/10.1182/blood-2018-05-850248

Published: 2018

Journal Articles

Primed CD4 T Cells to an Intracellular Alloantigen Facilitate Alloimmunization Following Subsequent Transfusion

Seema R Patel, BS, PhD, Ashley L Bennett, BA, Patricia E Zerra, MD, Satheesh Chonat, MD, Cheryl Maier, MD PhD, Sean R Stowell, MD PhD

Blood (2017) 130 (Supplement 1): 768.

https://doi.org/10.1182/blood.V130.Suppl_1.768.768

Published: 2017

Journal Articles

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Paul Rennert, PhD, Christine Ambrose, PhD, Lihe Su, PhD, Fay Dufort, PhD, Lan Wu, PhD, Andreas Hombach, PhD, Hinrich Abken, PhD, Roy Lobb, PhD

Blood (2017) 130 (Supplement 1): 4457.

https://doi.org/10.1182/blood.V130.Suppl_1.4457.4457

Published: 2017

Journal Articles

Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy

Jaclyn Rosenthal, BSN, Ammar S. Naqvi, PhD, Gerald Wertheim, MD PhD, Michele Paessler, D.O., Susan R. Rheingold, MD, Andrei Thomas-Tikhonenko, PhD, Vinodh Pillai, MD, PhD

Blood (2017) 130 (Supplement 1): 1331.

https://doi.org/10.1182/blood.V130.Suppl_1.1331.1331

Published: 2017

Journal Articles

Use of Flow Cytometry to Evaluate the Immunophenotypic Profile of Patients with Chronic Lymphocytic Leukemia from Rio Grande Do Norte State, Brazil

Aldair Paiva, MD, Gabriela VA Alves, PhD, Lorena KF Silva, Daniela GB Albuquerque, Francisco F Nascimento, Jr., MD, Rodrigo Villar Freitas, MD, Dany GKC Silva, Marcelo Rocha Barbosa, MD, Geraldo Barroso Cavalcanti, Jr., PhD

Blood (2017) 130 (Supplement 1): 5325.

https://doi.org/10.1182/blood.V130.Suppl_1.5325.5325

Published: 2017

Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD

Blood (2017) 130 (Supplement 1): 2765.

https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765

Published: 2017

Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 2782.

https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782

Published: 2017

Journal Articles

Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19

Mireya Paulina Velasquez, MD, Arpad Szoor, MD PhD, Challice L. Bonifant, MD PhD, Abishek Vaidya, Lorenzo Brunetti, MD, Michael C Gundry, BS, Robin Parihar, MD PhD, Margaret Goodell, PhD, Stephen Gottschalk, MD

Blood (2016) 128 (22): 4560.

https://doi.org/10.1182/blood.V128.22.4560.4560

Published: 2016

Journal Articles

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

Luciana De Luca, Giovanni D'Arena, MD, Vittorio Simeon, PhD, Stefania Trino, PhD, Ilaria Laurenzana, PhD, Antonella Caivano, Francesco La Rocca, Oreste Villani, MD, Giovanna Mansueto, MD, Silvia Deaglio, MD PhD, Idanna Innocenti, MD, Luca Laurenti, Stefano Molica, MD, Giuseppe Pietrantuono, MD, Angelo De Stradis, Luigi Del Vecchio, MD, Pellegrino Musto, MD

Blood (2016) 128 (22): 4375.

https://doi.org/10.1182/blood.V128.22.4375.4375

Published: 2016

Journal Articles

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Paul Michael Maciocia, BSc,MBBS,MRCP, Patrycja Wawrzyniecka, MSc, Brian Philip, PhD, Ida Ricciardelli, PhD, Ayse U. Akarca, BSc, Shimobi Onuoha, PhD, David Cole, PhD, Andrew Sewell, PhD, Karl S Peggs, MD, David C. Linch, MD MRCP, MB BCh, BA, Teresa Marafioti, MD, Martin A Pule, MD PhD

Blood (2016) 128 (22): 811.

https://doi.org/10.1182/blood.V128.22.811.811

Published: 2016

Journal Articles

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Jennifer N. Brudno, MD, Victoria Shi, David Stroncek, MD, Stefania Pittaluga, MD PhD, Jennifer A. Kanakry, MD, Lauren M. Curtis, MD, Juan C. Gea-Banacloche, MD, Steven Pavletic, MD, Mohammad-Hadi Bagheri, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2016) 128 (22): 999.

https://doi.org/10.1182/blood.V128.22.999.999

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Clonal B-Cell Lymphocytosis with Mariginal-Zone Features: Comparison with Overt Splenic Marginal-Zone Lymphomas in 77 Patients from a Monocentric Series

Oncogenic Cooperation between EGR1 and BRD4 in Diffuse Large B Cell Lymphoma

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Myc and the Warburg Effect

CAR T Cell Cytotoxicity Is Dependent on Death Receptor-Driven Apoptosis

Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

The cells are ambiguous, not the message

Primed CD4 T Cells to an Intracellular Alloantigen Facilitate Alloimmunization Following Subsequent Transfusion

CAR19 T Cells Redirected to Novel Antigens Mediate Robust Cytotoxicity Against Diverse Malignancies

Semi-Quantitative Analysis of CD19 and CD22 Expression in B-Lymphoblastic Leukemia and Implications for Targerted Immunotherapy

Use of Flow Cytometry to Evaluate the Immunophenotypic Profile of Patients with Chronic Lymphocytic Leukemia from Rio Grande Do Norte State, Brazil

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19

Characterization and Prognostic Relevance of Circulating Microvesicles in Chronic Lymphocytic Leukemia

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only